DHR vs QGEN vs A Stock Comparison

Danaher, Qiagen and Agilent Technologies Prices as of Nov 4, 2026 Peers: Industry group
1 more company in this comparison (RVTY) Create a free account to keep reading and compare up to 10 companies.
DHR Danaher Corp /De/
$234.94 +6.2% 1M +9.9% 1Y
Market cap
$161.04B
P/E
37.2x
Revenue (TTM)
$25.61B
Div. yield
–
Life Sciences Tools Healthcare
2 wins
QGEN Qiagen N.V.
$50.82 +11.0% 1M +9.3% 1Y
Market cap
$11.03B
P/E
26.9x
Revenue (TTM)
$2.10B
Div. yield
–
Life Sciences Tools Healthcare
3 wins
A Agilent Technologies, Inc.
$177.23 +3.5% 1M +21.3% 1Y
Market cap
$48.95B
P/E
34.0x
Revenue (TTM)
$7.37B
Div. yield
0.01%
Life Sciences Tools Healthcare
6 wins

Head to Head

11 decided of 12

Agilent Technologies leads on 6 of the 12 questions below (Agilent Technologies 6, Qiagen 3, Danaher 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionDHRQGENALeader
Larger companyMarket capitalisation $161.04B $11.03B $48.95B DHR
Cheaper on earningsLower P/E, profitable companies only 37.2x 26.9x 34.0x QGEN
Cheaper on forward earningsLower price / next fiscal year consensus EPS 25.8x 21.6x 27.1x QGEN
Faster revenue growthRevenue growth, trailing twelve months +5.5% +3.0% +8.6% A
More profitableNet margin, trailing twelve months 16.9% 19.5% 19.5% A
Better return on capitalReturn on invested capital 5.8% 7.9% 13.1% A
Less leveragedLower net debt / EBITDA 2.6x 1.3x 1.1x A
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.01% –
Better 1-year returnPrice return, last 12 months +9.9% +9.3% +21.3% A
Better 5-year returnAnnualised price return, 5 years -4.3%/yr -3.4%/yr +2.5%/yr A
Less volatileAnnualised volatility, 1 year 30.8% 35.4% 32.6% DHR
Higher overall scoreMean of the five percentile scores vs peers 61/100 71/100 62/100 QGEN

Percentile Scorecard

DHRQGENA

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisDHRQGENA
Valuation 71 #67 of 229 75 #58 of 229 57 #99 of 229
Growth 26 #164 of 221 30 #156 of 221 35 #144 of 221
Profitability 86 #31 of 209 93 #16 of 209 92 #17 of 209
Financial Health 48 #126 of 240 64 #86 of 240 56 #106 of 240
Shareholder Returns 72 #41 of 146 94 #10 of 146 68 #48 of 146
Overall 61 71 62
  • DHR ranked among 248 companies in Medical Devices and Diagnostics
  • QGEN ranked among 248 companies in Medical Devices and Diagnostics
  • A ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodDHRQGENASPY
1 month +6.2%+11.0%+3.5% -1.0%
3 months +17.7%+21.2%+25.6% -0.4%
6 months +34.3%+47.6%+50.6% +4.5%
Year to date +2.6%+7.4%+30.2% +12.4%
1 year +9.9%+9.3%+21.3% +13.6%
3 years +18.7%+16.1%+62.6% +76.4%
3 years, per year +5.9%+5.1%+17.6% +20.8%
5 years -19.6%-16.1%+13.3% +63.7%
5 years, per year -4.3%-3.4%+2.5% +10.4%
10 years +205.4%+64.8%+299.9% +267.7%
10 years, per year +11.8%+5.1%+14.9% +13.9%

Risk

MeasureDHRQGENASPY
Volatility, 1Y 30.8%35.4%32.6% 12.8%
Downside volatility, 1Y 32.0%30.1%27.9% 12.7%
Beta vs S&P 500, 1Y 0.500.430.93 1.00
Return / volatility, 1Y 0.320.260.65 1.06
Max drawdown, 5Y -50.8%-48.2%-39.6% -25.4%
From 52-week high -2.9%-8.7%-2.4% -1.6%
52-week high $242.05$55.66$181.54 $779.14
52-week low $161.91$32.63$110.24 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleDHRQGENA
P/E now vs peer median 38.2xmedian 28.5x 27.0xmedian 28.5x 34.7xmedian 28.5x
P/S now vs peer median 6.5xmedian 2.9x 5.2xmedian 2.9x 6.8xmedian 2.9x
EV/EBITDA now vs peer median 23.7xmedian 18.5x 18.2xmedian 18.5x 27.3xmedian 18.5x
P/FCF now vs peer median 28.9xmedian 26.7x 11.1xmedian 26.7x 39.4xmedian 26.7x
P/B now vs peer median 3.1xmedian 2.3x 3.3xmedian 2.3x 6.8xmedian 2.3x
PEG now vs peer median -4.76median 0.93 6.60median 0.93 3.53median 0.93

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsDHRQGENA
Revenue $25.61B $2.10B $7.37B
Gross profit $15.01B $1.31B $3.97B
Operating income $5.22B $445.43M $1.64B
Net income $4.33B $409.32M $1.44B
Free cash flow $5.73B $991.33M $1.27B
R&D $1.67B $194.67M $485.00M
EPS (diluted) $6.13 $1.87 $5.09
Cash & equivalents $5.68B $768.50M $1.76B
Total debt $26.48B $1.64B $3.95B
Shares (diluted) 706.80M 218.88M 283.00M
Enterprise value $140.70B $6.80B $41.84B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricDHRQGENA
P/E 38.2x 27.0x 34.7x
P/FCF 28.9x 11.1x 39.4x
P/Operating cash flow 24.1x 16.8x 31.1x
P/S 6.5x 5.2x 6.8x
P/B 3.1x 3.3x 6.8x
P/Tangible book 5.1x 3.7x 7.7x
EV/EBITDA 23.7x 18.2x 27.3x
EV/EBIT 35.7x 26.7x 31.8x
EV/Revenue 7.3x 5.7x 7.1x
EV/FCF 32.5x 12.0x 41.2x
EV/Operating cash flow 27.1x 18.1x 32.4x
PEG (3Y EPS CAGR) -4.76 6.60 3.53

Growth

14 metrics
MetricDHRQGENA
Revenue growth (1Y) 5.5% 3.0% 8.6%
Revenue CAGR (3Y) 1.3% 2.0% 1.8%
Gross profit growth (1Y) 3.9% 1.7% 11.2%
Gross profit CAGR (3Y) 1.2% 1.3% 3.7%
Operating income growth (1Y) 13.1% -4.9% 13.5%
Operating income CAGR (3Y) -3.8% 3.3% 5.1%
Net income growth (1Y) 23.6% 143.9% 18.0%
Net income CAGR (3Y) -9.9% 6.7% 8.3%
EPS growth (1Y) 24.8% 6.6% 18.9%
EPS CAGR (3Y) -8.0% 4.1% 9.8%
Operating cash flow growth (1Y) 8.6% -3.0% 7.6%
Operating cash flow CAGR (3Y) -5.3% 8.0% -1.9%
Free cash flow growth (1Y) 14.2% 2.3% 16.5%
Free cash flow CAGR (3Y) -5.8% 10.5% -3.7%

Profitability

14 metrics
MetricDHRQGENA
Gross margin 58.6% 62.2% 53.8%
EBITDA margin 30.7% 31.0% 25.9%
Operating margin 20.4% 21.2% 22.2%
Pretax margin 18.8% 22.0% 22.5%
Net margin 16.9% 19.5% 19.5%
FCF margin 22.4% 47.2% 17.2%
Operating cash flow margin 26.8% 31.2% 21.8%
Return on equity 8.2% 12.2% 19.9%
Return on assets 4.7% 7.0% 10.7%
Return on invested capital 5.8% 7.9% 13.1%
Return on capital employed 6.2% 8.5% 14.6%
Asset turnover 0.3x 0.4x 0.5x
Cash conversion (OCF / net income) 1.6x 1.6x 1.1x
Stock comp / revenue 1.3% 2.1% 1.8%

Financial Health

11 metrics
MetricDHRQGENA
Debt / assets 28.4% 27.9% 28.3%
Debt / equity 0.5x 0.5x 0.5x
Net debt / EBITDA 2.6x 1.3x 1.1x
Debt / FCF 4.6x 1.7x 3.1x
Liabilities / assets 42.5% 43.0% 47.3%
Equity / assets 57.5% 57.0% 52.7%
Interest coverage 14.5x 11.3x 15.5x
Current ratio 1.6x 2.8x 2.1x
Quick ratio 1.1x 2.0x 1.4x
Cash ratio 0.6x 1.4x 0.8x
Altman Z-score 3.77 4.11 5.85

Shareholder Returns

7 metrics
MetricDHRQGENA
Dividend yield 0.6% 5.2% 0.6%
Net buyback yield 0.5% 0.6% 0.6%
Shareholder yield 1.2% 5.8% 1.2%
Payout ratio (earnings) – – 19.9%
Payout ratio (FCF) – – 22.6%
Dividend growth (1Y) – – 2.1%
Dividend CAGR (3Y) – – 3.1%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusDHRQGENA
Forward P/E 25.8xFY2026 21.6xFY2026 27.1xFY2026
EPS, next fiscal year $9.11FY2026 $2.35FY2026 $6.54FY2026
EPS growth, next FY +16.8%FY2026 -1.3%FY2026 +17.0%FY2026
EPS growth, the year after +8.0% +17.4% +0.3%
Revenue, next fiscal year $27.01BFY2026 $2.25BFY2026 $7.87BFY2026
Revenue growth, next FY +9.9%FY2026 +7.8%FY2026 +15.3%FY2026
Revenue growth, the year after -1.9% -2.8% -5.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersDHRQGENA
Held by institutions 81.9% 67.3% 92.6%
Institutions holding 2,120 338 1,126
Change in shares held, QoQ +1.1% +16.5% +3.2%
Institutions buying 842 216 602
Institutions selling 1,015 86 351
Buyers to sellers 0.83 2.51 1.72

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

DHRQGENA
DHR 1.00 0.38 0.61
QGEN 0.38 1.00 0.37
A 0.61 0.37 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, DHR, QGEN and A?

Danaher (DHR) is the largest by market capitalisation: Danaher (DHR) $161.04B, Qiagen (QGEN) $11.03B, Agilent Technologies (A) $48.95B.

Which stock is cheaper, DHR, QGEN and A?

Qiagen (QGEN) trades on the lowest price-to-earnings ratio (Danaher (DHR) 37.2x, Qiagen (QGEN) 26.9x, Agilent Technologies (A) 34.0x). On next year's consensus earnings, Qiagen (QGEN) is cheapest (Danaher (DHR) 25.8x, Qiagen (QGEN) 21.6x, Agilent Technologies (A) 27.1x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Agilent Technologies (A) grew revenue fastest over the trailing twelve months: Danaher (DHR) +5.5%, Qiagen (QGEN) +3.0%, Agilent Technologies (A) +8.6%.

Which company is more profitable?

Agilent Technologies (A) has the highest net margin (Danaher (DHR) 16.9%, Qiagen (QGEN) 19.5%, Agilent Technologies (A) 19.5%). On return on invested capital, Agilent Technologies (A) leads (Danaher (DHR) 5.8%, Qiagen (QGEN) 7.9%, Agilent Technologies (A) 13.1%).

Which stock has performed better?

Over the past year Agilent Technologies (A) returned the most: Danaher (DHR) +9.9%, Qiagen (QGEN) +9.3%, Agilent Technologies (A) +21.3%. Over five years, Agilent Technologies (A) compounded fastest (Danaher (DHR) -4.3%/yr, Qiagen (QGEN) -3.4%/yr, Agilent Technologies (A) +2.5%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Danaher (DHR) 0.00%, Qiagen (QGEN) 0.00%, Agilent Technologies (A) 0.01%. Danaher (DHR) and Qiagen (QGEN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Danaher (DHR) has been the steadiest (Danaher (DHR) 30.8%, Qiagen (QGEN) 35.4%, Agilent Technologies (A) 32.6%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, DHR, QGEN and A?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Agilent Technologies (A) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.